Recent News

• 09.16.2025 - September 2025 – The Scientist
• 09.16.2025 - Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
• 09.16.2025 - Immuneering Appoints Dr. Thomas Schall as Chairman of the Board
• 09.10.2025 - Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
• 09.10.2025 - Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
• 08.26.2025 - Immuneering Announces Closing of $25 Million Private Placement
• 08.26.2025 - Immuneering Announces Closing of $25 Million Private Placement
• 08.25.2025 - Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
• 08.25.2025 - Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
• 08.21.2025 - Immuneering Announces $25 Million Private Placement

Recent Filings

• 09.09.2025 - D Notice of Exempt Offering of Securities
• 09.08.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 09.08.2025 - EFFECT Notice of Effectiveness
• 09.03.2025 - S-3 Registration statement under Securities Act of 1933
• 08.25.2025 - EX-99.1 EX-99.1
• 08.25.2025 - 8-K Current report
• 08.20.2025 - EFFECT Notice of Effectiveness